Correction to: Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS study

Affiliations

¹ Shanghai Changzheng Hospital, Shanghai, China.
² Seoul National University Bundang Hospital, Seongnam, South Korea.
³ Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
⁴ Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
⁵ First Hospital of Jilin University, Changchun, China.
⁶ Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
⁷ Chonnam National University Medical School, Hwasun, Jeollanamdo, South Korea.
⁸ College of Medicine, First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China.
⁹ Tianjin Cancer Hospital, Tianjin, China.
¹⁰ Hong Kong Sanatorium & Hospital, Happy Valley, Hong Kong, China.
¹¹ Janssen Research & Development, LLC, Spring House, Raritan, PA, USA.
¹² Johnson & Johnson (China) Investment Ltd, Beijing, China.
¹³ IQVIA, Shanghai, China.
¹⁴ Xian Janssen Pharmaceutical Ltd, Shanghai, China.
¹⁵ Xian Janssen Pharmaceutical Ltd, Beijing, China.
¹⁶ Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. houjian@medmail.com.cn.
¹⁷ Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China. wangjx@ihcams.ac.cn.

Published Erratum

Weijun Fu et al. Ann Hematol. 2024 Nov.

. 2024 Nov;103(11):4835-4836.

doi: 10.1007/s00277-024-06020-3.

¹ Shanghai Changzheng Hospital, Shanghai, China.
² Seoul National University Bundang Hospital, Seongnam, South Korea.
³ Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
⁴ Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
⁵ First Hospital of Jilin University, Changchun, China.
⁶ Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
⁷ Chonnam National University Medical School, Hwasun, Jeollanamdo, South Korea.
⁸ College of Medicine, First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China.
⁹ Tianjin Cancer Hospital, Tianjin, China.
¹⁰ Hong Kong Sanatorium & Hospital, Happy Valley, Hong Kong, China.
¹¹ Janssen Research & Development, LLC, Spring House, Raritan, PA, USA.
¹² Johnson & Johnson (China) Investment Ltd, Beijing, China.
¹³ IQVIA, Shanghai, China.
¹⁴ Xian Janssen Pharmaceutical Ltd, Shanghai, China.
¹⁵ Xian Janssen Pharmaceutical Ltd, Beijing, China.
¹⁶ Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. houjian@medmail.com.cn.
¹⁷ Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China. wangjx@ihcams.ac.cn.

No abstract available

Erratum for

Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Study.
Fu W, Bang SM, Huang H, Kim K, Li W, An G, Lee JJ, Cai Z, Jin J, Wang Y, Chim CS, Carson R, Liu R, Zhao M, Chen X, Cui C, Hou J, Wang J. Fu W, et al. Ann Hematol. 2025 Jan;104(1):515-525. doi: 10.1007/s00277-024-05958-8. Epub 2024 Sep 4. Ann Hematol. 2025. PMID: 39227450 Free PMC article. Clinical Trial.